A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities-Reference-Cited by-同舟云学术

A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities

Published:2020-09-14 Issue:11 Volume:25 Page:e1589-e1592
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Naidoo Jarushka¹²,Suresh Karthik³

Affiliation:

1. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA

2. Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland, USA

3. Division of Pulmonary and Critical Care Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

Abstract

This commentary outlines the strategy employed by a multidisciplinary immune-related toxicity team to evaluate patients who may be at high risk for the development of immune-related toxicity, in particular, those with preexisting lung conditions and subsequent immune-related pneumonitis.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2020-0266

Reference19 articles.

1. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy;Naidoo;J Clin Oncol,2017

2. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: Incidence and risk factors;Suresh;J Thorac Oncol,2018

3. Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer;Nishino;Cancer Immunol Res,2016

4. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis;Lomax;Int J Rheum Dis,2017

5. A multidisciplinary toxicity team for cancer immunotherapy-related adverse events;Naidoo;J Natl Compr Canc Netw,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges;Journal of Thoracic Oncology;2023-11

2. Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis – The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging;Neoplasia;2023-05

3. An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis;Current Oncology;2022-06-17